Hogar y Estilo de Vida
5 hábitos para añadir años a tu vida
Ver más
Políticas Médicas
Las políticas médicas son documentos que definen el reconocimiento de cubierta para tecnologías, procedimientos y tratamientos. Las declaraciones de necesidad médica en las políticas, sobre si una tecnología, procedimiento, tratamiento, suplido, equipo, medicamento u otro servicio mejora el resultado en la salud de la población para la cual dicha tecnología o tratamiento fue diseñado se basan en evidencia científica, estudios clínicos y opiniones profesionales de nuestros proveedores y de las organizaciones médicas reconocidas.
Cada documento desplegado en este sitio Web se provee con propósitos informativos solamente y no es una autorización, explicación de beneficios o un contrato. El recibir beneficios está sujeto a la satisfacción de todos los términos y condiciones de la cubierta. La tecnología médica cambia constantemente y nos reservamos el derecho de revisar y actualizar nuestras políticas periódicamente.
| ID | Título | Última Revisión | Siguiente Revisión | Descripción | Acceso |
|---|---|---|---|---|---|
| M5.001.007 | Somatuline® Depot; Lanreotide | May 10, 2024 | May 20, 2025 | Somatuline® depot; lanreotide is used to treat people with acromegaly (condition in which the body... | Ver |
| M5.001.008 | Simponi ARIA® (golimumab) | May 10, 2024 | May 20, 2025 | Golimumab is in a class of drugs called biologics. golimumab is a treatment for adults with moderate to... | Ver |
| M5.001.009 | Stelara® (ustekinumab) | May 10, 2024 | May 20, 2025 | Stelara is a human igg1κ monoclonal antibody that binds with high affinity and specificity to the p40... | Ver |
| M5.001.010 | Infliximab | May 10, 2024 | May 20, 2025 | Description- intro infliximab (remicade) is a tumor necrosis factor α (tnf-α) blocking agent... | Ver |
| M5.001.011 | Erythropoiesis Stimulating Agents | May 10, 2024 | May 20, 2025 | Endogenous erythropoietin is a glycoprotein hematopoietic growth factor that regulates hemoglobin levels in... | Ver |
| M5.001.012 | Vascular Endothelial Growth Factor Inhibitors for the Treatment of Ophthalmological Diseases | May 10, 2024 | May 20, 2025 | Vascular endothelial growth factor has been implicated in the pathogenesis of a variety of ocular vascular... | Ver |
| M5.001.013 | Ruconest | May 10, 2024 | May 20, 2025 | C-1 esterase inhibitor protein is one of nine complement proteins found in the blood that works with the... | Ver |
| M5.001.014 | Immune Globulin | May 10, 2024 | May 20, 2025 | Immune globulin (also referred to as gamma globulin or immunoglobulin) is a therapeutic compound prepared... | Ver |
| M5.001.015 | Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adult Patients | May 10, 2024 | May 20, 2025 | Hereditary transthyretin-mediated amyloidosis (hattr) is a rare, progressive, and fatal autosomal dominant... | Ver |
| M5.001.016 | Lumasiran for Primary Hyperoxaluria Type 1 | May 10, 2024 | May 20, 2025 | Primary hyperoxalurias are a group of rare genetic diseases. there are 3 subtypes each resulting in the... | Ver |
| M5.001.017 | Hemophilia Antihemophilic Factor | May 10, 2024 | May 20, 2025 | The hemophilias are a group of related bleeding disorders that most commonly are inherited. inherited... | Ver |
| M5.001.018 | Nucala® (mepolizumab) | Jun 25, 2024 | Jun 20, 2025 | Mepolizumab is an interleukin-5 antagonist monoclonal antibody (igg1 kappa) for the add-on maintenance... | Ver |
| M5.001.019 | Fasenra® (benralizumab) | Jun 25, 2024 | Jun 20, 2025 | Benralizumab is an interleukin-5 antagonist monoclonal antibody (igg1 kappa) for the add-on maintenance... | Ver |
| M5.001.020 | Givosiran for Acute Hepatic Porphyria | Jun 25, 2024 | Jun 20, 2025 | Acute hepatic porphyria (ahp) is a rare disease with a prevalence of 5 to 10 cases/100,000 people in the us... | Ver |
| M5.001.021 | Biological Treatments for Refractory Myasthenia Gravis | Jun 25, 2024 | Jun 20, 2025 | Myasthenia gravis is an autoimmune neuromuscular disorder characterized by fluctuating motor weakness... | Ver |
| M5.001.022 | Ultomiris® (ravulizumab-cwvz) | Oct 09, 2024 | Jun 20, 2025 | Ravulizumab-cwvz is a complement inhibitor indicated as a treatment for adult patients, 18 years and older,... | Ver |
| M5.001.023 | Soliris (eculizumab) | Aug 22, 2024 | Aug 20, 2025 | Soliris is a complement inhibitor indicated for the treatment of patients with paroxysmal nocturnal... | Ver |
| M5.001.024 | Adstiladrin® (nadofaragene firadenovec-vncg) | Feb 20, 2025 | Oct 20, 2025 | Adstiladrin is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult... | Ver |
| M7.001.001 | May 10, 2024 | Policy Archived | Studies have generally found that laser treatment can be effective at lightening port wine stains. the... | Ver | |
| MP.001.001 | Dose rounding of drugs covered under the Medical Benefit | May 10, 2024 | May 20, 2025 | ... | Ver |
